Experts at a roundtable in Boston, Massachusetts, on November 19, 2025, discussed multidisciplinary strategies for obesity ...
Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced ...
In an interview with The American Journal of Managed Care®, Levin explained that for patients whose medications are covered ...
Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...
The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...
A majority of counties experienced growth in penetration of Medicare value-based approaches: Medicare Shared Savings Program (MSSP) accountable care organizations (ACOs) and Medicare Advantage (MA).
In the commercial market, PBMs must now pass through 100% of rebates and other remuneration to payers and comply with robust new transparency and reporting rules enforced by CMS, which can penalize ...
The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by ...
In an interview, Jackson Peter Kim, MD, clinical assistant professor in the Division of Nephrology at Stanford Health Care, ...
Panelists discuss how incorporating advanced practice providers (APPs) into structured health-system pathways expands ...
The role of polygenic risk scores in patients with idiopathic pulmonary fibrosis (IPF) may be influenced by telomere length, ...
Panelists discuss how effective teamwork among advanced practice providers (APPs), neurologists, and primary care providers leads to better outcomes. They stress role clarity, mutual respect, and open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results